Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9782939 | 0.95 | THRA (0.46) | THRATHRBNR5A1TSHRPLA2G4B | |
| SCHEMBL15404359 | 0.90 | NR5A1 (0.51) | THRATHRBNR5A1TSHRPLA2G4B | |
| SCHEMBL19549600 | 0.90 | NR5A1 (0.51) | THRATHRBNR5A1TSHRPLA2G4B | |
| SCHEMBL2094045 | 0.90 | NR5A1 (0.51) | THRATHRBNR5A1TSHRPLA2G4B | |
| SCHEMBL28645328 | 0.90 | NR5A1 (0.51) | THRATHRBNR5A1TSHRPLA2G4B | |
| SCHEMBL16314448 | 0.85 | THRA (0.56) | THRATHRBNR5A1TSHRPLA2G4B | |
| SCHEMBL19612480 | 0.83 | PLA2G4B (0.58) | THRATHRBNR5A1TSHRPLA2G4B | |
| SCHEMBL13339091 | 0.82 | THRA (0.53) | THRATHRBNR5A1TSHRPLA2G4B | |
| SCHEMBL27404637 | 0.81 | MAPK1 (0.44) | — | |
| SCHEMBL10983336 | 0.81 | NQO1 (0.48) | TSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000071118-A1 | PHOSPHOLIPASE A2-SPECIFIC INHIBITING COMPOUNDS | UNIVERSITE PARIS 7 - DENIS DIDEROT (FR) | 2000-11-30 | — | — | WO | disclosed |